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Summary Background: Many epidemiological studies have assessed the prevalence
of respiratory allergic disorders in confined geographical locations. However, no
study has yet established nationally prevalence data in a uniform manner
representing whole countries and, thus, enabling cross-national comparisons.
Methods: In 10 European countries, screening of random, representative samples
of telephone numbers identified the target population aged 16–60. The inclusion
criteria were a positive reporting of respiratory allergy to named allergens and,
concomitantly, an unassisted description of appropriate symptoms. To obtain a truly
representative, national prevalence of each country, the data were weighted against
the actual sex and age composition.
Results: 31,065 screening interviews were performed. The nationally balanced
prevalence varied significantly among the 10 countries (Po0:001) from 11.7% in
Spain to 33.6% in Italy. The overall weighted prevalence for Europe was 24.4%.
Comparing males and females, overall, the odds-ratio was 0.874 (Po0:001). For
age intervals of 16–29, 30–49, and 50–60 years, the odds-ratios for males were 1.104
(Po0:088), 0.827 (Po0:001), and 0.658 (Po0:001), respectively. The prevalence
correlated inversely with age.
Conclusions: Respiratory allergic disorders constitute a huge health problem in
Europe, and the impact may be increasing as the prevalence is highest among young
people.
& 2003 Elsevier Ltd. All rights reserved.
Introduction
The prevalence of respiratory allergic disorders has
been assessed in several epidemiological studies
and the associated health problems because of hay
fever and asthma have been increasing during the
last few decades.1–5 These studies have been
performed in a confined geographical location and
no study has yet measured nationally balanced
respiratory allergy prevalence in a uniform manner
enabling a cross-national comparison.
Irrespective of specific approach and applied
methodology, the epidemiological studies within
allergic respiratory diseases have established pre-
valence data for certain well-defined regions within
a country, often around an allergy centre of
excellence. Additionally, it is the prevalence of
asthma or hay fever, which has been examined, and
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not the prevalence of respiratory allergy. In such
studies, the reported allergy prevalence in Europe
varies more than five-fold among the different
countries.5–7 These variations may be due to actual
differences between countries, or rather regions,
but may also be influenced by different means of
collecting data conceivably representing the na-
tion. Especially in large nations like Italy and Spain,
large variations have been reported.5
The aims of this study called ‘‘AllergyFLiving &
Learning’’ were (1) to evaluate the national
prevalence of respiratory allergic diseases in the
populations of 10 European countries by national
screening of random and representative samples of
the populations, (2) to identify which factors are
important to the allergic patient’s perception and
management of own respiratory disease and influ-
ence on social life, (3) to investigate the potential
consequences of specific diagnosis and treatment
for the patient, and (4) to make comparisons
between the 10 European countries included.
This study is a report on nationally balanced
prevalence of respiratory allergy in 10 European
countries, i.e. Austria, Denmark, Finland, Ger-
many, Italy, The Netherlands, Norway, Spain,
Sweden, and the United Kingdom.
Materials and methods
The methodology relevant for the reported
prevalence results is described below. The full
AllergyFLiving & Learning study set-up has been
described in detail elsewhere.8
Methodology
The target population aged 16–60 was identified by
telephone screening of random, national, repre-
sentative samples of telephone numbers. The
inclusion criteria of the study were a positive
reporting of respiratory allergy to pollens (i.e.
trees, grasses, or weeds), house dust mites,
moulds, dog, cat or other animals and, concomi-
tantly, an unassisted description of appropriate
symptoms.8 In order to be eligible for participation,
though asked, the respondent should not necessa-
rily be able to report a specific medical diagnosis
such as rhinitis or hay fever. Consequently, the
population included in the study reported to be
suffering from a respiratory allergy, irrespective of
the degree of symptoms and specific diagnosis.
To avoid the bias of parents answering on behalf
of their children, the study did not include
children. People older than 60 years of age were
not included as they often have non-allergic
respiratory conditions that may mimic allergic
respiratory disorders.
If the first intended contact with a household was
negative, the interviewer asked to talk to a second
person from the same household. When including
these data in the calculation, an estimate of the
household prevalence of perceived respiratory
allergy was established. For further explanation
of the methodology for these calculations in Den-
mark, The Netherlands, Austria, the UK, Spain and
Italy, data for the calculation of both the nationally
balanced prevalence and the household prevalence
were established simultaneously with the potential
conduct of the full AllergyFLiving & Learning
interview.8 Initially, Germany, Finland and Sweden
stored data from first and potentially second
contact in one database and the household pre-
valence was thereby established. The conduct of
481, 570, 1276, and 1505 additional screening
interviews in Finland, Germany, Sweden, and Nor-
way, respectively, allowed the calculation of the
remaining prevalence figures. For Sweden, Finland
and Germany, the second screening rounds included
only the first contact made, i.e. the person with
the first upcoming birthday. In Finland, Sweden,
and Norway, respectively, the second round was
conducted 9–12 weeks after the original study and
for Germany 22–23 weeks later.
Ethical standards
All interviews were conducted in accordance with
the Code of Conduct of the European Standards of
Market Analysis and Research (ESOMAR, Amster-
dam, The Netherlands). This code of conduct
guarantees full anonymity and integrity of the
respondents.
Weighting and statistical methods
In order to estimate the overall prevalence of all 10
European countries, the national prevalence of
each country was weighted against the size of the
respective population. The sizes of the national
populations were obtained from the European
Commission, Brussels.9
Stratified analyses were performed to evaluate
the association between prevalence of allergy and
country, between prevalence of allergy and three
age intervals of 16–29, 30–49, and 50–60 years, and
between prevalence of allergy and gender. Con-
trolling for confounding variables, the Mantel–
Haenzel procedure was used to calculate summary
statistics.
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A two-sided P value of 0.05 was the criterion for
statistical significance. All statistical analyses were
made with the SAS software package (version 6.12).
Results
A total of 31,065 screening interviews were
performed in the 10 European countries establish-
ing data for calculation of nationally balanced and
household prevalence of respiratory allergy.
The nationally balanced prevalence varied sig-
nificantly among the countries (Po0:001) from
11.7% in Spain to 33.6% in Italy (Table 1). Spain
and Austria had significantly lower nationally
balanced prevalence than all other countries. Spain
was significantly lower than Austria, and Italy had a
significantly higher prevalence than all other
countries (Po0:05) (Table 1). Household preva-
lence ranged from 18.1% in Spain to 39.0% in
Sweden (Table 1).
The overall prevalence of respiratory allergic
disorders in the 10 countries was 24.4% when
weighting by population sizes (Table 2).
Within national sub-groups, age and gender, the
prevalence of respiratory allergic disorders was
calculated in percentage and as odds-ratios
(Tables 3 and 4). Data were breakdowns of the
nationally balanced prevalence of all countries but
The Netherlands, where the figures were a break-
down of the household prevalence.
For all countries pooled, the prevalence was
reduced in the respondents the older they were
(Po0:001), in Austria (Po0:001), the UK Po0:002),
Spain (Po0:001), Italy (Po0:001), and in The
Netherlands (household, Po0:001) (Table 3).
For males, the reduction in prevalence the older
they were was significant for all countries pooled
(Po0:001), for Austria (Po0:001), Germany
(Po0:001), Italy (Po0:001), The Netherlands
(household, Po0:001), Spain (Po0:001), and for
the UK (Po0:002). For females, the trend of the
individual countries was less strong. However, a
significant age-related reduction was observed
when pooling all countries (Po0:001), and for
individual countries this was also the case in both
The Netherlands (household) and Spain (Po0:001)
(Table 3).
In all countries but Sweden, females reported a
higher prevalence of respiratory allergic disorders;
this was statistically significant for all countries
pooled (Po0:001), in Spain (Po0:001) and in the
UK (Po0:049) (Table 3).
Comparing males and females, overall, the odds-
ratio was 0.874 (Po0:001) (Table 4). For the age
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Table 2 Prevalence of respiratory allergic disorders in the 10 countries based on nationally balanced prevalence
and weighted against the size of national populations.
Austria Denmark Finland Germany Italy The
Netherlands
Norway Spain Sweden The
UK
Prevalence (%) 15.9 20.6 26.0 23.5 33.6 24.2 26.8 11.7 26.8 26.2
Populationn (1000) 8075 5295 5147 82.057 57.563 15.654 4418 39.348 8848 59.090
Allergic population
(1000)
1288 1090 1338 19.291 19.331 3783 1186 4599 2371 15.511
Weighted prevalence 24.4%
It is assumed that the nationally balanced prevalence in the age group of 16–60-year-olds is applicable to the total population of
each country.
nRef. [8].
Table 3 Prevalence of respiratory allergic disorders within national sub-groups, age and gender.
Austria Denmark Finland Germany Italy The Netherlands Norway Spain Sweden The UK
Basis 3223 2162 481 570 3761 2276 1505 6519 1276 3482
Subgroups
16–29 years (%) 19.8n 23.2 31.4 29.2 37.4n 34.0n 29.9 17.6n 31.0 28.8nn
30–49 years (%) 15.6n 20.1 26.8 23.0 33.0n 26.5n 26.6 10.2n 25.0 26.7 nn
50–60 years (%) 12.0n 18.9 22.4 19.4 29.7 n 18.4n 24.5 7.1n 25.3 20.3nn
Males (%) 15.7 19.1 22.1 21.6 32.6 26.0 24.6 10.2n 27.4 24.2nnn
Females (%) 16.2 21.9 28.7 24.6 34.6 26.6 28.3 12.3n 25.9 27.3nnn
Males
16–29 years (%) 21.3n 22.6 33.3 37.3n 42.8n 34.7 n 28.0 16.5n 30.9 30.0nn
30–49 years (%) 15.1n 19.4 23.0 21.0n 29.1n 26.3n 25.2 6.9n 25.9 23.8nn
50–60 years (%) 9.7 n 14.7 15.9 7.5n 24.5n 14.5n 20.3 4.9n 26.6 16.1nn
Females
16–29 years (%) 18.4 23.6 30.0 24.1 33.6 33.6n 31.1 18.3n 30.7 28.2
30–49 years (%) 16.1 20.8 29.3 24.0 35.8 26.5n 27.5 11.4n 23.6 28.2
50–60 years (%) 13.8 22.1 27.2 26.4 33.4 20.3n 27.5 7.8n 24.2 22.6
Data are breakdowns of the nationally balanced prevalence of all countries but The Netherlands, where the figures are a
breakdown of household prevalence. Italic entries, taken columnwise or rowwise, not interrupted by extra spaces differ
significantly, nPo0:001;nn Po0:002;nnn Po0:049:
Table 4 Differences in prevalence of respiratory allergy between genders in three age groups.
Austria Denmark Finland Germany Italy The
Netherlands
Norway Spain Sweden The
UK
All
countries
Odds-ratio
16–29 years 1.2 0.9 1.2 1.9 1.5 1.1 0.9 0.9 1.0 1.1 1.104
30–49 years 0.9 0.9 0.7 0.8 0.7 1.0 0.9 0.6 1.1 0.8 0.827
50–60 years 0.7 0.6 0.5 0.2 0.6 0.7 0.7 0.6 1.1 0.7 0.658
Age pooled 0.96 0.84 0.71 0.89 0.91 0.95 0.83 0.73 1.09 0.85 0.874
P-value
16–29 years 0.297 0.769 0.766 0.106 0.002 0.797 0.523 0.339 0.966 0.566 0.088
30–49 years 0.586 0.568 0.268 0.564 0.003 0.929 0.479 0.001 0.516 0.034 0.001
50–60 years 0.101 0.029 0.091 0.006 0.006 0.119 0.110 0.078 0.644 0.078 0.001
Age pooled 0.631 0.108 0.106 0.388 0.149 0.572 0.109 0.001 0.493 0.049 0.001
The top half of the table shows odds-ratios for males against females having respiratory allergy, listed according to age, and the
bottom half shows the corresponding P-values.
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intervals of 16–29, 30–49, and 50–60 years, the
odds-ratios for males were 1.104 (Po0:088), 0.827
(Po0:001), and 0.658 (Po0:001), respectively.
Discussion
In the present study, the nationally balanced
prevalence of respiratory allergy was established
for 10 European countries representing a total
population exceeding 285 million inhabitants by
assessing truly random, national representative
samples of the total population.
The survey methodology applied has not pre-
viously been used for assessing prevalence of
chronic diseases such as respiratory allergic dis-
orders but one recent study assesses asthma control
in patients identified by telephone screening.10
Nevertheless, the telephone-based sampling tech-
niques are widely used and statistically fully
validated, and subsequently recognised as a means
of establishing valuable and reliable nationally
balanced data in many areas. Additionally, the
massive number of studies implying this methodol-
ogy have created an enormous base of experience
in both practical and theoretical statistical aspects
of surveys based on telephone interviews.11–13
The present study samples were truly random
and representative of each nation; however, an
objective disease parameter such as positive skin
prick test or the measurement of specific IgE was
not done or asked for as an inclusion criterion. This
would have caused logistic and interpretational
difficulties and bias. In addition, in order to further
minimise potential bias, information on the pur-
pose of the study was kept from the respondents
until completion of the screening phase.
Studies that previously have addressed the
prevalence of allergic diseases selected the study
samples in a limited geographical area defined as,
e.g. a specific postal code or the geographical
territory of an allergy centre of excellence.3–5
Such a sample may rarely be characterised as
random and representative of the full population of
a country. The advantage is the opportunity of
verifying the diagnosis by objective disease para-
meters, which may be necessary should a precise
characterisation of the disease be needed14 or for
the performance of specific laboratory tests.
In 1998, Linneberg et al.4 found that the
prevalence of allergic rhinitis symptoms in persons
at the age of 15–41 living in the capital region of
Denmark was up to 35.1%. In the present study, the
Danish nationally balanced prevalence of allergic
respiratory disorders was 20.6%. This discrepancy
could partly or fully be explained by the difference
in sampling area but underlines the magnitude of
respiratory allergy.
Unfortunately, it is a necessity for inclusion of
objective disease parameters that the potential
patient physically visits a medical clinic and under-
goes testing in order to obtain the specific test
result. Such a procedure is time consuming and
perhaps even involves expenses. Therefore, it may
cause a serious skew of the sample composition.
Additionally, the potential patient may feel a loss
of anonymity.
Actually, at no point did the set-up include a
direct confrontation of the respondent with anyone
and the full anonymity was not broken or jeopar-
dised as the telephone contact represented the
only means of contact.
The prevalence of respiratory allergic disorders
established in this study equals 24.4% when
weighting by the population of the 10 countries.
This number is within the range of earlier reports
on asthma and hay fever prevalence15–17 and
verifies the immense health problem that respira-
tory allergic diseases represent.
The Mediterranean countries, Italy and Spain,
though located in the same geographical region,
represent the highest and lowest prevalence of this
study. Findings in the ISAAC study5,14 may support
the difference found. However, in this study the
prevalence of rhinitis and asthma in both Italy and
Spain varies considerably among participating
centres. The reasons for the differences in mea-
sured national prevalence in the present study and
in other European epidemiological studies are not
easily explained and need further examination
potentially including demographic and socio-eco-
nomic parameters.
The occurrence of respiratory allergic disorders is
inversely correlated with age in the 10 European
countries included. This finding may support the
increase in asthma prevalence reported in a
number of studies.18,19 Furthermore, the result
suggests that the increase in asthma is likely to
originate from an increase in allergic sensitisation
and not solely in severity of respiratory symptoms.
This is in accordance with the result of Upton
et al.,3 who observed that the increase in asthma
between 1972–1976 and 1996 was solely explained
by an increase in allergic asthma, whereas the
prevalence of non-allergic asthma was unchanged.
Though just outside the interval of statistical
significance, there is a trend that young boys may
be more susceptible to allergic respiratory dis-
orders than girls. This is reverted when maturing.
It may be speculated whether this is due to shift
in the sex distribution of respiratory allergic
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disorders, an indication of boys ‘‘grow out of their
allergic disease’’ easier than girls, or merely the
fact that females express the disease later in life
than males. It is a well-known fact that asthma is
more prevalent in boys and the influence of sex and
age appears to be real. The effect of sex and age on
the prevalence of wheeze and asthma in 11–16-
year-old children was examined by Venn et al.,20
who found that the prevalence of wheeze de-
creased with age in boys and increased with age in
girls.
In conclusion, the AllergyFLiving & Learning
study provides evidence for a high prevalence of
respiratory allergy in Europe and national differ-
ences are present. A clear inverse age relation to
respiratory allergy was seen. Lastly, in addition,
respiratory allergy was influenced by gender, i.e.
more prevalent in younger males and older
females.
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